These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10895051)

  • 1. Inhibition of ras oncogene: a novel approach to antineoplastic therapy.
    Scharovsky OG; Rozados VR; Gervasoni SI; Matar P
    J Biomed Sci; 2000; 7(4):292-8. PubMed ID: 10895051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking oncogenic Ras signaling for cancer therapy.
    Adjei AA
    J Natl Cancer Inst; 2001 Jul; 93(14):1062-74. PubMed ID: 11459867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer: The Ras renaissance.
    Ledford H
    Nature; 2015 Apr; 520(7547):278-80. PubMed ID: 25877186
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
    Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense inhibition of ras p21 expression that is sensitive to a point mutation.
    Chang EH; Miller PS; Cushman C; Devadas K; Pirollo KF; Ts'o PO; Yu ZP
    Biochemistry; 1991 Aug; 30(34):8283-6. PubMed ID: 1883816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. v-K-ras leads to preferential farnesylation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid pathway.
    Laezza C; Di Marzo V; Bifulco M
    Proc Natl Acad Sci U S A; 1998 Nov; 95(23):13646-51. PubMed ID: 9811854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
    Nammi S; Lodagala DS
    Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Ras for cancer treatment: the search continues.
    Baines AT; Xu D; Der CJ
    Future Med Chem; 2011 Oct; 3(14):1787-808. PubMed ID: 22004085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS: A Promising Therapeutic Target for Cancer Treatment.
    Wu HZ; Xiao JQ; Xiao SS; Cheng Y
    Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Mutant KRAS for Anticancer Therapy.
    Chen F; Alphonse MP; Liu Y; Liu Q
    Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenes and oncoproteins in occupational carcinogenesis.
    Brandt-Rauf PW
    Scand J Work Environ Health; 1992; 18 Suppl 1():27-30. PubMed ID: 1357742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transduction effect of antisense K-ras on malignant phenotypes in gastric cancer cells.
    Song JJ; Lee H; Kim E; Kim YS; Yoo NC; Roh JK; Kim BS; Kim J
    Cancer Lett; 2000 Aug; 157(1):1-7. PubMed ID: 10893435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of Current Immunotherapies Targeting Mutated KRAS Cancers.
    Hoo WPY; Siak PY; In LLA
    Curr Top Med Chem; 2019; 19(23):2158-2175. PubMed ID: 31483231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting RAS: The Elusive Prize.
    Bates SE
    Clin Cancer Res; 2015 Apr; 21(8):1796. PubMed ID: 25878359
    [No Abstract]   [Full Text] [Related]  

  • 15. Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects.
    Marcus K; Mattos C
    Clin Cancer Res; 2015 Apr; 21(8):1810-8. PubMed ID: 25878362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of proto-oncogene activation in carcinogenesis.
    Anderson MW; Reynolds SH; You M; Maronpot RM
    Environ Health Perspect; 1992 Nov; 98():13-24. PubMed ID: 1486840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Farnesyl transferase inhibitors--a novel agent for breast cancer].
    Zhang M; Jiang D
    Ai Zheng; 2006 Apr; 25(4):516-20. PubMed ID: 16613692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of the immune response and tumor growth by activated Ras.
    Weijzen S; Velders MP; Kast WM
    Leukemia; 1999 Apr; 13(4):502-13. PubMed ID: 10214854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibitors of isoprenylation of ras p21].
    Yoshimatsu K
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of being K-Ras.
    Ellis CA; Clark G
    Cell Signal; 2000 Jul; 12(7):425-34. PubMed ID: 10989276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.